NEW YORK (GenomeWeb) – Thermo Fisher Scientific and BioAnalytix today announced they will develop advanced analytical profiling platforms and applications for characterizing biologic and biosimilar drugs.

Minor differences in the structures of biological drugs can significantly affect their safety and efficacy, and sophisticated analytic workflows are necessary for accurate characterization. Thermo Fisher and BioAnalytix aim to develop analytical profiling standards in order to support and accelerate the development of such therapeutics, they said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.